Гематология / лейкозы / лимфомы

Blood Cancer Research Award Advances Lymphoma Clinical Trials

Blood Cancer Research Award Advances Lymphoma Clinical Trials University of Miami

IMS 2026: Key Updates Across The Multiple Myeloma Paradigm

Novel CAR-T Therapy for Hard-to-Treat Multiple Myeloma Shows Promising Safety and Durable Responses | Newswise

Novel CAR-T Therapy for Hard-to-Treat Multiple Myeloma Shows Promising Safety and Durable Responses | Newswise newswise.com

Ciltacabtagene Autoleucel Manufacturing, Debulking, and Bridging in Multiple Myeloma

Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma

EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma

Introduction to CELMoDs in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma: Case-Based Discussion — The Comorbid, Higher-Risk Patient, and Program Conclusions

Relapsed/Refractory Multiple Myeloma: Case-Based Discussion — The Fit, Immunotherapy-Eligible Patient in Second Line

Relapsed/Refractory Multiple Myeloma: Case-Based Discussion — Rapidly Progressive Earlier-Relapse Disease

Relapsed/Refractory Multiple Myeloma: Debate — Contextualizing Safety and Sequencing BCMA-Directed Therapies

Relapsed/Refractory Multiple Myeloma: Debate — Treatment Selection Between CAR T-Cell and Bispecific Approaches in Second-Line Disease

Relapsed/Refractory Multiple Myeloma: Safety and Real-World Management of BCMA-Directed Therapies

Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 Long-Term Outcomes and Treatment-Free Remission With Cilta-cel

Relapsed/Refractory Multiple Myeloma: MajesTEC-9 and Teclistamab Monotherapy in Lenalidomide and Anti-CD38 Double-Refractory Disease